Heat Biologics, Inc.
Find Ratings ReportsHEAT BIOLOGICS INC's gross profit margin for the third quarter of its fiscal year 2020 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. HEAT BIOLOGICS INC is extremely liquid. Currently, the Quick Ratio is 30.91 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 630.67% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q3 FY20 | Q3 FY19 |
---|---|---|
Net Sales ($mil) | 0.85 | 0.01 |
EBITDA ($mil) | -8.81 | -5.06 |
EBIT ($mil) | -8.9 | -5.12 |
Net Income ($mil) | -8.85 | -6.2 |
Balance Sheet | Q3 FY20 | Q3 FY19 |
---|---|---|
Cash & Equiv. ($mil) | 117.31 | 15.02 |
Total Assets ($mil) | 129.71 | 24.45 |
Total Debt ($mil) | 1.94 | 0.35 |
Equity ($mil) | 121.54 | 16.63 |
Profitability | Q3 FY20 | Q3 FY19 |
---|---|---|
Gross Profit Margin | -1036.82 | -84350.0 |
EBITDA Margin | -1036.82 | -84350.0 |
Operating Margin | -1047.29 | -85266.67 |
Sales Turnover | 0.03 | 0.13 |
Return on Assets | -17.68 | -88.41 |
Return on Equity | -18.87 | -129.97 |
Debt | Q3 FY20 | Q3 FY19 |
---|---|---|
Current Ratio | 31.34 | 3.29 |
Debt/Capital | 0.02 | 0.02 |
Interest Expense | 0.0 | 0.0 |
Interest Coverage | 0.0 | 0.0 |
Share Data | Q3 FY20 | Q3 FY19 |
---|---|---|
Shares outstanding (mil) | 22.43 | 4.76 |
Div / share | 0.0 | 0.0 |
EPS | -0.42 | -1.26 |
Book value / share | 5.42 | 3.49 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 4016505.0 | 3.0914426E7 |
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.11 indicates a significant discount versus the S&P 500 average of 4.11 and a significant discount versus the subsector average of 11.24. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, HEAT BIOLOGICS INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HTBX NM | Peers 32.89 | HTBX NM | Peers 87.81 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. HTBX's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. HTBX's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
HTBX NM | Peers 21.08 | HTBX NA | Peers 0.69 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. HTBX's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
HTBX 1.11 | Peers 11.24 | HTBX 52.24 | Peers 10.80 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. HTBX is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. HTBX is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
HTBX 31.17 | Peers 1710.59 | HTBX 39.76 | Peers 695.47 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. HTBX is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. HTBX significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||